Ono Pharmaceutical Co Ltd (OPHLY)

Currency in USD
3.70
+0.02(+0.54%)
Closed·

OPHLY Financial Summary

Key Ratios

P/E Ratio15.69
Price/Book0.96
Debt / Equity18.61%
Return on Equity6.32%
Dividend Yield0.00%
EBITDA88.69B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 106.55%
Dividend Yield
-
Industry Median 2.83%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.032 / 0.0305
Revenue / Forecast
774.38M / 808.77M
EPS Revisions
Last 90 days

FAQ

What were Ono Pharmaceutical Co's earnings for the latest quarter?

The Ono Pharmaceutical Co EPS (TTM) is 106.55. Ono Pharmaceutical Co reported sales of 112,309.00, net income of -6,545.00, and EPS of -0.03 for the latest quarter.

What was Ono Pharmaceutical Co's net income for the latest quarter?

Ono Pharmaceutical Co's net income for the latest quarter was -6,545.00.

How did Ono Pharmaceutical Co's performance compare year-over-year in the latest quarter?

The company's revenue moved from 134,223.00 in the previous quarter to 112,309.00 in the latest quarter, and net income moved from 14,951.00 to -6,545.00 compared to the previous quarter.

What is Ono Pharmaceutical Co's net profit margin on a TTM basis?

Ono Pharmaceutical Co's trailing twelve months (TTM) net profit margin is 10.28%.

How does Ono Pharmaceutical Co's debt to equity ratio compare to industry standards?

Ono Pharmaceutical Co's total debt-to-equity ratio is 18.61%.

What is Ono Pharmaceutical Co's return on investment on a TTM basis?

Ono Pharmaceutical Co's trailing twelve months (TTM) return on investment (ROI) is 6.32%.

Did Ono Pharmaceutical Co gain or lose cash last quarter?

In the latest quarter, Ono Pharmaceutical Co's net change in cash was 43,585.00 million.

What were Ono Pharmaceutical Co's total assets and liabilities in the latest quarter?

As of the latest quarter, Ono Pharmaceutical Co reported total assets of 1,064,046.00 million and total liabilities of 148,296.00 million.

How has Ono Pharmaceutical Co's total revenue grown this year?

Ono Pharmaceutical Co's total revenue was 134,223.00 in the previous quarter and 112,309.00 in the latest quarter.

What is Ono Pharmaceutical Co's gross margin on a TTM basis?

Ono Pharmaceutical Co's trailing twelve months (TTM) gross margin is 69.61%.

What was Ono Pharmaceutical Co's revenue per share for the latest quarter?

Ono Pharmaceutical Co's revenue per share for the latest quarter was 43.82.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.